News | May 31, 2023
Synexa Joins CEPI in advancing global epidemic preparedness and response
Synexa joins CEPI’s esteemed Central Lab Network to improve global epidemic preparedness
Synexa joins CEPI’s esteemed Central Lab Network to improve global epidemic preparedness
This action follows the recent acceptance of the Marketing Authorization Application (MAA) for Pfizer’s RSV vaccine candidate by the European Medicines Agency
Biocytogen will provide a license to Hansoh Pharma for their selected fully human antibody molecules
If approved, the vaccine could help simplify the meningococcal vaccination schedule and provide the broadest serogroup coverage of any meningococcal vaccine
48-week data from MOMENTUM phase III clinical trial show momelotinib maintained total symptom response
Through lifestyle modifications, ADORE will assess the progress of patients based on parameters like reduction in blood sugar levels and weight, among others
The total quantity traded at NSE stood at 34,653 shares and the total turnover stood at Rs. 117.23 lakh.
Ryzneuta is a novel dimeric G- CSF long-acting fusion protein without pegylation. The Biologics License Application (BLA) of Ryzneuta is currently under late-stage review by the US FDA for Chemotherapy-Induced Neutropenia (CIN)
Dr. Mandaviya agreed to host the Stop TB Partnership’s 36th Board meeting on March 25-26, 2023 in Varanasi
The CRL did not identify any outstanding scientific issues with the product.
Subscribe To Our Newsletter & Stay Updated
